title: Omarigliptin for the treatment of type 2 diabetes.
abstract: Omarigliptin is a new once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the treatment of type 2 diabetes. It is indicated to have favorable effects on glycosylated hemoglobin (HbA1c), fasting and postmeal plasma glucose. It potently but reversibly inhibits DPP-4 enzyme, which prolongs the circulating half-life of glucagon-like peptide-1 that increases insulin secretion in a glucose-dependent manner. Benefiting from glucose-dependent insulin secretion, omarigliptin is associated with low risk of hypoglycemia. In contrast to the once-daily dipeptidyl peptidase-4 inhibitors (e.g., alogliptin, linagliptin, sitagliptin), once-weekly omarigliptin can improve patients' adherence and thus achieve optimal therapeutic efficacy. Herein, I review the pharmacological and clinical profile of omarigliptin for the treatment of type 2 diabetes based on the available clinical data.
authors.affiliation: Department of Endocrinology, Yuyao People's Hospital, Yuyao, Zhejiang, China. tanxueying@163.com.
authors.forename: Xueying
authors.initials: X
authors.lastname: Tan
mesh_terms: D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006574:Heterocyclic Compounds, 2-Ring / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011714:Pyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C587539:2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine; D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006574:Heterocyclic Compounds, 2-Ring; D011714:Pyrans
keywords: DPP-4 inhibitor; Omarigliptin; Once-weekly administration; Type 2 diabetes